Drugs.com - Pharma Industry News

FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma

MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.Monjuvi is a humanized Fc-modified cytolytic CD19-targeting...

Jun 23, 2025 - 23:05
 0
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
MONDAY, June 23, 2024 -- The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.Monjuvi is a humanized Fc-modified cytolytic CD19-targeting...
Read More

Tags:

Previous Article

Trump's War With Iran Could Send Gas Prices Through The Roof

Next Article

STAT+: Health insurers promise to reduce barriers to care under pressure from Tr...

Related Posts

Hypertension Is Most Common Chronic Condition in People Aged 85 Years and Older

Hypertension Is Most Common Chronic Condition in People...

Jun 20, 2025  0

Psilocybin Plus Psychotherapy Offers Lasting Benefit in Cancer, Depression

Psilocybin Plus Psychotherapy Offers Lasting Benefit in...

Jun 16, 2025  0

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Ga...

Jun 5, 2025  0